Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Garsorasib plus anlotinib vs chemoimmunotherapy as first-line treatment for KRAS G12C-mutant advanced non-squamous NSCLC
ChiCTR2500110453Phase 4Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of garsorasib and anlotinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Shanghai Chest Hospital. Primary endpoints: Objective Response Rate (ORR) in single-arm phase and Progression-Free Survival (PFS) in randomized controlled phase. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
garsorasibanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500110453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110453.